Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NextCure, Inc. (NXTC : NSDQ)

• Company Description    NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. Number of Employees: 43

• Price / Volume Information    Yesterday's Closing Price: $0.45 Daily Weekly Monthly 20 Day Moving Average: 210,815 shares Shares Outstanding: 28.05 (millions) Market Capitalization: $12.51 (millions) Beta: 1.04 52 Week High: $1.82 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 53.26% 45.23% 12 Week -41.11% -36.38% Year To Date -42.15% -39.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9000 VIRGINIA MANOR ROAD SUITE 200 - BELTSVILLE,MD 20705 USA ph: 240-399-4900 fax: - ir@nextcure.com http://www.nextcure.com

• General Corporate Information    Officers Michael Richman - President and Chief Executive Officer David Kabakoff - Chairman Steven P. Cobourn - Chief Financial Officer Anne Borgman - Director Ellen G. Feigal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 65343E108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 28.05 Most Recent Split Date: (:1) Beta: 1.04 Market Capitalization: $12.51 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.22 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 36.07% vs. Previous Quarter: 4.88% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - -70.16 12/31/24 - -68.38 09/30/24 - -62.50 ROA 03/31/25 - -58.10 12/31/24 - -57.24 09/30/24 - -53.67 Current Ratio 03/31/25 - 10.26 12/31/24 - 7.50 09/30/24 - 9.07 Quick Ratio 03/31/25 - 10.26 12/31/24 - 7.50 09/30/24 - 9.07 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - 1.99 12/31/24 - 2.34 09/30/24 - 2.70 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00

Powered by Zacks Investment Research ©